CN118369101A - 治疗癌症和肿瘤的方法 - Google Patents

治疗癌症和肿瘤的方法 Download PDF

Info

Publication number
CN118369101A
CN118369101A CN202280081569.8A CN202280081569A CN118369101A CN 118369101 A CN118369101 A CN 118369101A CN 202280081569 A CN202280081569 A CN 202280081569A CN 118369101 A CN118369101 A CN 118369101A
Authority
CN
China
Prior art keywords
group
substituted
cancer
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280081569.8A
Other languages
English (en)
Chinese (zh)
Inventor
G·K·劳埃德
R·莫汉拉尔
J·R·托纳拉
黄岚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeyondSpring Pharmaceuticals Inc
Original Assignee
BeyondSpring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BeyondSpring Pharmaceuticals Inc filed Critical BeyondSpring Pharmaceuticals Inc
Publication of CN118369101A publication Critical patent/CN118369101A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280081569.8A 2021-10-07 2022-10-06 治疗癌症和肿瘤的方法 Pending CN118369101A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163253332P 2021-10-07 2021-10-07
US63/253,332 2021-10-07
PCT/US2022/077702 WO2023060200A1 (en) 2021-10-07 2022-10-06 Methods for treating cancers and tumors

Publications (1)

Publication Number Publication Date
CN118369101A true CN118369101A (zh) 2024-07-19

Family

ID=85804784

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280081569.8A Pending CN118369101A (zh) 2021-10-07 2022-10-06 治疗癌症和肿瘤的方法

Country Status (6)

Country Link
US (1) US20240408082A1 (https=)
EP (1) EP4412613A4 (https=)
JP (1) JP2024538730A (https=)
CN (1) CN118369101A (https=)
CA (1) CA3234699A1 (https=)
WO (1) WO2023060200A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005212399B2 (en) * 2004-02-04 2011-09-22 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
AU2016229294B2 (en) * 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
MX2021001762A (es) * 2018-08-16 2021-04-19 Beyondspring Pharmaceuticals Inc Metodo y composicion para estimular la respuesta inmunitaria.
JP2022513038A (ja) * 2018-11-14 2022-02-07 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合薬を使用する癌の治療方法

Also Published As

Publication number Publication date
WO2023060200A1 (en) 2023-04-13
CA3234699A1 (en) 2023-04-13
EP4412613A4 (en) 2025-10-22
US20240408082A1 (en) 2024-12-12
JP2024538730A (ja) 2024-10-23
EP4412613A1 (en) 2024-08-14

Similar Documents

Publication Publication Date Title
US11685738B2 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
CN118369101A (zh) 治疗癌症和肿瘤的方法
ES2981607T3 (es) Activadores de Tie-2 para uso en el tratamiento de la presión intraocular
JP6963545B2 (ja) 癌を治療するための併用療法
US8372830B2 (en) Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
US10639304B2 (en) Kinase inhibitors
KR20170141757A (ko) 테트라하이드로나프티리디닐 프로피온산 유도체 및 이의 용도
US6632832B1 (en) Anti-cancer activity of carvedilol and its isomers
CN112166111A (zh) 治疗纤维化疾病的方法
CN113613654B (zh) 普那布林在制备增加非转移性乳腺癌患者触珠蛋白的药物中的用途
TW201912153A (zh) 用於治療ｂ型肝炎的化合物、醫藥組合物及方法
KR20160106042A (ko) 암 치료용 약학적 배합물
US6566395B1 (en) Methods of treating proliferative disorders
US20160339001A1 (en) Novel Methods for Treating Cancer
US10449182B2 (en) Sorafenib derivatives as p21 inhibitors
US10537563B2 (en) Methods for treating ocular disease using inhibitors of CSF-1R
HK40109587A (zh) 治疗癌症和肿瘤的方法
US20240051969A1 (en) Ror-gamma inhibitors for the treatment of ror-gamma-dependent cancer
JP2026509292A (ja) 腫瘍学的併用療法及びその使用方法
HK40104383A (zh) 用於治疗血液病的化合物和组合物
HK40031549B (zh) 用於治疗血液病的化合物和组合物
HK1241361B (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
HK1229744B (zh) 2-乙酰基萘并[2，3-b]呋喃-4，9-二酮用於治疗癌症的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40109587

Country of ref document: HK